Xi Y, Xu P (2021) Global colorectal cancer burden in 2020 and projections to 2040. Transl Oncol 14(10):101174

Article  PubMed  PubMed Central  Google Scholar 

Raschellà G, Melino G, Malewicz M (2017) New factors in mammalian DNA repair-the chromatin connection. Oncogene 36(33):4673–4681

Article  PubMed  PubMed Central  Google Scholar 

Zhao W, Hu H, Mo Q, Guan Y, Li Y, Du Y, Li L (2019) Function and mechanism of combined PARP-1 and BRCA genes in regulating the radiosensitivity of breast cancer cells. Int J Clin Exp Pathol 12(10):3915–3920

CAS  PubMed  PubMed Central  Google Scholar 

Knijnenburg TA, Wang L, Zimmermann MT, Chambwe N, Gao GF, Cherniack AD, Fan H, Shen H, Way GP, Greene CS, Liu Y, Akbani R, Feng B, Donehower LA, Miller C, Shen Y, Karimi M, Chen H, Kim P, Jia P, Shinbrot E, Zhang S, Liu J, Hu H, Bailey MH, Yau C, Wolf D, Zhao Z, Weinstein JN, Li L, Ding L, Mills GB, Laird PW, Wheeler DA, Cancer Genome Atlas Research Network, Shmulevich I, Monnat RJ Jr, Xiao Y, Wang C (2018) Genomic and Molecular Landscape of DNA Damage Repair Deficiency across The Cancer Genome Atlas. Cell Rep. 23(1):239-254.e6

Article  CAS  PubMed  PubMed Central  Google Scholar 

Vilar E, Gruber SB (2010) Microsatellite instability in colorectal cancer-the stable evidence. Nat Rev Clin Oncol 7(3):153–162

Article  CAS  PubMed  PubMed Central  Google Scholar 

Maede Y, Shimizu H, Fukushima T, Kogame T, Nakamura T, Miki T, Takeda S, Pommier Y, Murai J (2014) Differential and common DNA repair pathways for topoisomerase I- and II-targeted drugs in a genetic DT40 repair cell screen panel. Mol Cancer Ther 13(1):214–220

Article  CAS  PubMed  Google Scholar 

Romesser PB, Capdevila J, Garcia-Carbonero R, Philip T, Fernandez Martos C, Tuli R, Rodriguez-Gutierrez A, Kuipers M, Becker A, Coenen-Stass A, Sarholz B, You X, Miller ED (2024) A Phase Ib Study of the DNA-PK Inhibitor Peposertib Combined with Neoadjuvant Chemoradiation in Patients with Locally Advanced Rectal Cancer. Clin Cancer Res 30(4):695–702

Article  CAS  PubMed  Google Scholar 

Samuels M, Falkenius J, Bar-Ad V, Dunst J, van Triest B, Yachnin J, Rodriguez-Gutierrez A, Kuipers M, You X, Sarholz B, Locatelli G, Becker A, Troost EGC (2024) A Phase 1 Study of the DNA-PK Inhibitor Peposertib in Combination With Radiation Therapy With or Without Cisplatin in Patients With Advanced Head and Neck Tumors. Int J Radiat Oncol Biol Phys 118(3):743–756

Article  PubMed  Google Scholar 

Blackford AN, Jackson SP (2017) ATM, ATR, and DNA-PK: The Trinity at the Heart of the DNA Damage Response. Mol Cell 66(6):801–817

Article  CAS  PubMed  Google Scholar 

Qian J, Liao G, Chen M, Peng RW, Yan X, Du J, Huang R, Pan M, Lin Y, Gong X, Xu G, Zheng B, Chen C, Yang Z (2024) Advancing cancer therapy: new frontiers in targeting DNA damage response. Front Pharmacol 15:1474337

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ngoi NYL, Westin SN, Yap TA (2022) Targeting the DNA damage response beyond poly(ADP-ribose) polymerase inhibitors: novel agents and rational combinations. Curr Opin Oncol 34(5):559–569

Article  CAS  PubMed  PubMed Central  Google Scholar 

Leichman L, Groshen S, O’Neil BH, Messersmith W, Berlin J, Chan E, Leichman CG, Cohen SJ, Cohen D, Lenz HJ, Gold P, Boman B, Fielding A, Locker G, Cason RC, Hamilton SR, Hochster HS (2016) Phase II Study of Olaparib (AZD-2281) After Standard Systemic Therapies for Disseminated Colorectal Cancer. Oncologist 21(2):172–177

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chen EX, Jonker DJ, Siu LL, McKeever K, Keller D, Wells J, Hagerman L, Seymour L (2016) A Phase I study of olaparib and irinotecan in patients with colorectal cancer: Canadian Cancer Trials Group IND 187. Invest New Drugs 34(4):450–457

Article  CAS  PubMed  Google Scholar 

Pishvaian MJ, Slack RS, Jiang W, He AR, Hwang JJ, Hankin A, Dorsch-Vogel K, Kukadiya D, Weiner LM, Marshall JL, Brody JR (2018) A phase 2 study of the PARP inhibitor veliparib plus temozolomide in patients with heavily pretreated metastatic colorectal cancer. Cancer 124(11):2337–2346

Article  CAS  PubMed  Google Scholar 

Ramos H, Soares MI, Silva J, Raimundo L, Calheiros J, Gomes C, Reis F, Monteiro FA, Nunes C, Reis S, Bosco B. 2021 A selective p53 activator and anticancer agent to improve colorectal cancer therapy. Cell Rep 35(2)

Smeby J, Kryeziu K, Berg KCG, Eilertsen IA, Eide PW, Johannessen B, Guren MG, Nesbakken A, Bruun J, Lothe RA, Sveen A (2020) Molecular correlates of sensitivity to PARP inhibition beyond homologous recombination deficiency in pre-clinical models of colorectal cancer point to wild-type TP53 activity. EBioMedicine 59:102923

Article  CAS  PubMed  PubMed Central  Google Scholar 

Shiloh Y, Ziv Y (2013) The ATM protein kinase: regulating the cellular response to genotoxic stress, and more. Nat Rev Mol Cell Biol 14(4):197–210

Article  CAS  PubMed  Google Scholar 

Menear KA, Adcock C, Boulter R, Cockcroft XL, Copsey L, Cranston A, Dillon KJ, Drzewiecki J, Garman S, Gomez S, Javaid H, Kerrigan F, Knights C, Lau A, Loh VM Jr, Matthews IT, Moore S, O’Connor MJ, Smith GC, Martin NM (2008) 4-[3-(4-cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one: a novel bioavailable inhibitor of poly(ADP-ribose) polymerase-1. J Med Chem 51(20):6581–6591

Article  CAS  PubMed  Google Scholar 

Xie YH, Chen YX, Fang JY (2020) Comprehensive review of targeted therapy for colorectal cancer. Signal Transduct Target Ther 5(1):22

Article  CAS  PubMed  PubMed Central  Google Scholar 

Harnor SJ, Brennan A, Cano C (2017) Targeting DNA-Dependent Protein Kinase for Cancer Therapy. ChemMedChem 12(12):895–900

Article  CAS  PubMed  Google Scholar 

Leahy JJ, Golding BT, Griffin RJ, Hardcastle IR, Richardson C, Rigoreau L, Smith GC (2004) Identification of a highly potent and selective DNA-dependent protein kinase (DNA-PK) inhibitor (NU7441) by screening of chromenone libraries. Bioorg Med Chem Lett 14(24):6083–6087

Article  CAS  PubMed  Google Scholar 

Imreh G, Norberg HV, Imreh S, Zhivotovsky B (2016) Chromosomal breaks during mitotic catastrophe trigger γH2AX-ATM-p53-mediated apoptosis. J Cell Sci 129(9):1950

Article  CAS  PubMed  Google Scholar 

Sun H, Cao S, Mashl RJ, Mo CK, Zaccaria S, Wendl MC, Davies SR, Bailey MH, Primeau TM, Hoog J, Mudd JL, Dean DA 2nd, Patidar R, Chen L, Wyczalkowski MA, Jayasinghe RG, Rodrigues FM, Terekhanova NV, Li Y, Lim KH, Wang-Gillam A, Van Tine BA, Ma CX, Aft R, Fuh KC, Schwarz JK, Zevallos JP, Puram SV, Dipersio JF, NCI PDXNet Consortium, Davis-Dusenbery B, Ellis MJ, Lewis MT, Davies MA, Herlyn M, Fang B, Roth JA, Welm AL, Welm BE, Meric-Bernstam F, Chen F, Fields RC, Li S, Govindan R, Doroshow JH, Moscow JA, Evrard YA, Chuang JH, Raphael BJ, Ding L (2021) Comprehensive characterization of 536 patient-derived xenograft models prioritizes candidatesfor targeted treatment. Nat Commun. 12(1):5086

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gao Y, Chaudhuri J, Zhu C, Davidson L, Weaver DT, Alt FW (1998) A targeted DNA-PKcs-null mutation reveals DNA-PK-independent functions for KU in V(D)J recombination. Immunity 9(3):367–376

Article  CAS  PubMed  Google Scholar 

Weng YR, Cui Y, Fang JY (2012) Biological functions of cytokeratin 18 in cancer. Mol Cancer Res 10(4):485–493

Article  CAS  PubMed  Google Scholar 

Patrick GP, Chad T, Gordon BM, Timothy AY (2019) State-of-the art strategies for targeting the DNA damage response in cancer. Nat Rev Clin Oncol 16(2):81–104

Article  Google Scholar 

Lord CJ, Ashworth A (2016) BRCAness revisited. Nat Rev Cancer 16(2):110–120

Article  CAS  PubMed  Google Scholar 

Collot T, Niogret J, Carnet M, Chevrier S, Humblin E, Favier L, Bengrine-Lefevre L, Desmoulins I, Arnould L, Boidot R (2021) PARP inhibitor resistance and TP53 mutations in patients treated with olaparib for BRCA-mutated cancer: Four case reports. Mol Med Rep 23(1):75

Article  CAS  PubMed  Google Scholar 

Kumar A, Gautam V, Sandhu A, Rawat K, Sharma A, Saha L (2023) Current and emerging therapeutic approaches for colorectal cancer: A comprehensive review. World J Gastrointest Surg 15(4):495–519